Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Genzyme in-licenses Isis' mipomersen

Isis (NASDAQ:ISIS) granted Genzyme (NASDAQ:GENZ) an exclusive, worldwide license to develop and commercialize mipomersen (formerly ISIS 301012) and

Read the full 181 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE